Achieve Life Sciences (ACHV) Total Current Liabilities (2010 - 2026)
Achieve Life Sciences (ACHV) posted Total Current Liabilities of $11.8 million for Q1 2026, up 30.29% on a QoQ basis from $9.1 million in Q4 2025, and up 65.96% year-over-year from $7.1 million in Q1 2025.
Achieve Life Sciences (ACHV) Total Current Liabilities (2010 - 2026) Analysis & Trends
Achieve Life Sciences' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $11.8 million for Q1 2026.
- Quarterly Total Current Liabilities rose 65.96% year-over-year to $11.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.8 million (up 65.96% YoY) and the FY2025 annual result came in at $9.1 million, up 35.92% from the prior year.
- Total Current Liabilities was $11.8 million for Q1 2026 at Achieve Life Sciences, up from $9.1 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $21.6 million in Q4 2022 and bottomed at $3.4 million in Q2 2023.
- A 5-year average of $10.6 million and a median of $8.6 million in 2025 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Current Liabilities soared 406.26% — and 2024, when it plunged 67.9%.
- Achieve Life Sciences' Total Current Liabilities stood at $21.6 million in 2022, then decreased by 3.64% to $20.8 million in 2023, then plunged by 67.9% to $6.7 million in 2024, then jumped by 35.92% to $9.1 million in 2025, then jumped by 30.29% to $11.8 million in 2026.
- Business Quant data shows ACHV's Total Current Liabilities at $11.8 million in Q1 2026, $9.1 million in Q4 2025, and $9.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Achieve Life Sciences | 2.54 Mn | 2.54 Mn | - | 11.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.83 Mn |
| Dec 31, 2025 | 9.08 Mn |
| Sep 30, 2025 | 9.73 Mn |
| Jun 30, 2025 | 8.57 Mn |
| Mar 31, 2025 | 7.13 Mn |
| Dec 31, 2024 | 6.68 Mn |
| Sep 30, 2024 | 6.72 Mn |
| Jun 30, 2024 | 13.70 Mn |
| Mar 31, 2024 | 20.57 Mn |
| Dec 31, 2023 | 20.81 Mn |
| Sep 30, 2023 | 4.08 Mn |
| Jun 30, 2023 | 3.45 Mn |
| Mar 31, 2023 | 20.30 Mn |
| Dec 31, 2022 | 21.60 Mn |
| Sep 30, 2022 | 6.92 Mn |
| Jun 30, 2022 | 5.36 Mn |
| Mar 31, 2022 | 4.01 Mn |
| Dec 31, 2021 | 4.55 Mn |
| Sep 30, 2021 | 3.08 Mn |
| Jun 30, 2021 | 4.67 Mn |